Crestor (Rosuvastatin) Cost in Nebraska 2026: Prices, Insurance, and Savings

Rosuvastatin calcium is the generic name for the medication sold under the brand Crestor (AstraZeneca), a statin (HMG-CoA reductase inhibitor) FDA-approved to lower LDL cholesterol and reduce cardiovascular risk. Generic rosuvastatin has been available from multiple manufacturers since 2016, and it is rated by the FDA as therapeutically equivalent (AB-rated) to brand Crestor.

The question worth asking is not "what does Crestor cost" but "am I actually being charged the generic rate, or is a plan, pharmacy, or prescriber accidentally routing me to the brand." Because the molecule has been off-patent for years, the generic is almost always the far cheaper and clinically equivalent option, and most of what determines a Nebraska patient's actual out-of-pocket cost is insurance tier placement and pharmacy choice, not the drug itself.

What actually drives your rosuvastatin cost in Nebraska

Three things determine what a Nebraska patient pays, far more than the drug's list price:

1. Brand versus generic. Brand Crestor has a manufacturer list price that is not what most patients pay and is not usable as a reliable "market price" for this article, since list prices change and rarely reflect real transaction cost. Generic rosuvastatin, dispensed under state generic-substitution rules unless a prescriber specifies otherwise, is the version almost every Nebraska patient with insurance or a discount card actually receives.
2. Insurance tier placement. Generic statins are commonly placed on a plan's lowest cost-sharing tier because they are inexpensive, off-patent, and guideline-recommended. Brand Crestor, when covered at all, is typically placed on a higher, non-preferred tier.
3. Pharmacy and program choice. Retail generic discount lists, warehouse-club pharmacies, prescription discount cards, and 340B pricing at qualifying safety-net clinics can all produce different cash prices for the same 30-day supply, and these prices shift over time.

Because cash and copay prices move month to month and pharmacy to pharmacy, this article does not publish a specific dollar figure as a fixed 2026 Nebraska price. Any number a reader sees for "Crestor cost in Nebraska" should be treated as a snapshot that needs to be re-checked at the pharmacy counter, not a fixed fact.

Does Nebraska Medicaid cover rosuvastatin or Crestor?

State Medicaid programs, including Nebraska's, generally follow a standard pattern: when a lower-cost, FDA-rated-equivalent generic exists, the brand is excluded from the preferred drug list or requires prior authorization demonstrating generic intolerance, while the generic is placed on a preferred tier with minimal copay. This general Medicaid drug-coverage structure is documented at the federal level by CMS and by state Medicaid utilization reporting.

What is established: generic statins as a class are widely covered as preferred generics across state Medicaid programs, consistent with the ACA's preventive-services requirement to cover USPSTF-recommended preventive statin therapy for eligible adults.

What requires current verification: the exact Nebraska Heritage Health managed-care organization names, specific copay amounts, and whether prior authorization applies at the 40 mg dose. Managed-care contracts and formularies change on an annual or more frequent basis, and this article does not have a verified, dated source confirming Nebraska's current plan-by-plan formulary details for rosuvastatin. A reader who needs a firm answer should call their specific Heritage Health plan or check the current Nebraska Medicaid preferred drug list directly.

• USPSTF statin recommendation (general policy basis): https://www.uspstf.org/recommendation/statin-use-in-adults-preventive-medication
• CMS Medicaid prescription drug coverage overview: https://www.medicaid.gov/medicaid/prescription-drugs/state-drug-utilization-data/index.html

Commercial insurance and Medicare Part D

Most commercial plans place generic statins, including rosuvastatin, on a preferred generic tier with low, flat copays; brand Crestor, if covered, generally sits on a non-preferred brand tier with a higher copay or coinsurance. This pattern is standard formulary design across payers rather than a Nebraska-specific rule, and specific tier and copay amounts vary by plan year and employer, so a reader should check their own plan's current formulary rather than assume a number.

Medicare Part D formularies commonly treat generic rosuvastatin similarly, as a low-tier generic. The Part D benefit structure itself, including the annual out-of-pocket cap and elimination of the prior "coverage gap," is set at the federal level and documented by CMS; specific plan tier placement and copay amounts still vary by the Part D plan a beneficiary selects and should be confirmed during the plan's current enrollment period.

• CMS Medicare prescription drug coverage: https://www.cms.gov/medicare/coverage/prescription-drug-coverage

Verification checklist: what's stable versus what changes

Use this to separate facts you can rely on without re-checking from facts that must be verified against a current, dated source before you act on them.

Compounded rosuvastatin: what's actually established

Under federal law (FDCA Section 503A), a licensed pharmacy may compound a patient-specific rosuvastatin preparation when a valid prescription exists and the compound is prepared by or under the supervision of a licensed pharmacist. This is a federal framework, not a Nebraska-specific allowance, and it is documented on the FDA's compounding policy page.

• FDA compounding laws and policies: https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies

Reasons a patient might reasonably consider a compounded formulation include a non-standard dose not manufactured commercially, or a documented excipient sensitivity to fillers or dyes used in manufactured tablets. Compounded drugs are not FDA-approved products; they do not go through the same premarket review as manufactured rosuvastatin, and their quality depends on the individual pharmacy's practices. A patient considering a compounded product should confirm the pharmacy's current state licensure and ask about its quality-assurance and potency-testing practices before switching from a manufactured generic that already has an established equivalence rating.

Telehealth prescribing

Telehealth prescribing of non-controlled medications like rosuvastatin is broadly permitted across most states, generally after a clinician reviews relevant labs (a lipid panel) and cardiovascular risk factors, consistent with how statin initiation is handled in person. Nebraska has its own telehealth regulatory framework administered through the Department of Health and Human Services. Because state telehealth rules are revised periodically, a reader should confirm the current requirements, including whether an in-person visit is ever required for a given prescriber type, directly against the current Nebraska DHHS regulation rather than relying on a citation to a specific past version of the rule.

The evidence behind prescribing rosuvastatin at all

Rosuvastatin's use for cardiovascular risk reduction rests on a substantial trial base, most notably a large randomized primary-prevention trial (commonly known as JUPITER) published in the New England Journal of Medicine that enrolled patients with elevated high-sensitivity C-reactive protein but LDL cholesterol below typical treatment thresholds, and reported a significant reduction in major cardiovascular events with rosuvastatin versus placebo. This trial's findings were incorporated into the risk-enhancing-factor framework of the ACC/AHA cholesterol management guideline. This article does not restate the trial's precise effect-size numbers (hazard ratio, confidence interval) because the specific citation could not be independently re-verified against the primary paper during this review; a clinician or editor citing exact figures should confirm them directly against the published trial before publishing a precise number.

What is established: rosuvastatin, alongside other statins, is guideline-recommended for defined groups, patients with atherosclerotic cardiovascular disease, LDL at or above very high thresholds, diabetes with additional risk factors in the 40 to 75 age range, and select higher-risk primary-prevention patients per USPSTF and ACC/AHA guidance. What is plausible but not the point of this cost-focused page: individualized dosing and risk stratification, which should come from a treating clinician, not from a cost article. What is not established here: any specific numeric price, copay, or state-formulary rule for 2026 that has not been re-checked against a current, dated primary source.

Dosing and monitoring, in general terms

Rosuvastatin is approved at 5 mg, 10 mg, 20 mg, and 40 mg taken once daily, with most adults starting at 10 mg or 20 mg. Because manufactured generic tablets across strengths are typically priced similarly by pharmacies, switching doses does not reliably change out-of-pocket cost the way it might for drugs priced per strength, but this should be confirmed at the specific pharmacy, since exact pricing structures vary.

Statin labeling no longer recommends routine periodic liver enzyme monitoring for most patients, following an FDA label revision years ago that reflected how rarely serious liver injury occurs with statin use; a baseline check is still reasonable. Creatine kinase testing is not routine but is appropriate if a patient develops new muscle pain or weakness. Muscle-related side effects are uncommon with statins as a class, though this article does not cite a precise incidence figure for rosuvastatin specifically without a verified primary source.

Seek urgent medical care for signs of a serious statin-related reaction: dark urine, severe unexplained muscle pain or weakness, yellowing of the skin or eyes, or signs of an allergic reaction. These warrant prompt evaluation rather than waiting for a routine follow-up.

Evidence boundary, in plain terms

Established: rosuvastatin's FDA-approved dosing range, its generic status since 2016, its AB-rating to brand Crestor, the general federal framework for 503A compounding, the general structure of Medicare Part D and Medicaid preferred-drug-list logic, and the guideline basis for statin use in defined risk groups.

Plausible but requiring current confirmation: specific Nebraska Medicaid MCO rules, specific commercial plan copay tiers, specific retail or discount-program cash prices, and the exact current text of Nebraska's telehealth regulation.

Not established on this page: any single fixed dollar figure as "the" 2026 Nebraska price for Crestor or generic rosuvastatin, and the precise numeric trial results for the primary-prevention statin trial referenced above, which need direct verification against the original publication before being cited as an exact figure.